Xvivo Perfusion (Xvivo) announced late Friday that the company has received premarket approval (PMA) for the XPS and STEEN Solution. We believe that the approval will be of high importance when working to increase the use of EVLP and will help solidify the investment story for Xvivo. The approval was, however, in line with expectations and does not impact our valuation.